Secondary carnitine deficiency can be caused by increased losses, pharmacological therapy, a number of inherited metabolic disorders [38], poor diet or malabsorption of carnitine, from increased renal tubular loss of free carnitine (Fanconi syndrome), haemodialysis, peritoneal dialysis, or the increased excretion of acylcarnitines[39] with certain drugs
Microinjection of ghrelin into the VTA and NAc increased feeding in rodents (Naleid et al., 2005
Moreover, semaglutide outperformed liraglutide in safety and efficacy
One thing that concerns me as the use of GLP-1 receptor agonists continues to grow, is how rarely we discuss muscle mass preservation during treatment
10.1089/jmf.2014.0138 7 AsmarA.MohandasR.WingoC
The second generation, like Wegovy and Zepbound, hit 25% or more on average with just one shot a week